Skip to content

Advertisement

  • Research
  • Open Access

The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study

Contributed equally
Health and Quality of Life Outcomes201816:180

https://doi.org/10.1186/s12955-018-1007-7

  • Received: 12 December 2017
  • Accepted: 3 September 2018
  • Published:

Abstract

Background

This study aimed to determine the socioeconomic and clinical characteristics affecting health-related quality of life (HRQoL) in patients with psoriasis.

Methods

A cross-sectional study was conducted between March and June 2015 using data obtained via an Internet-based survey completed by a psoriasis patient group in Korea. The survey included items regarding demographic, socioeconomic, and clinical characteristics and HRQoL. Patients’ HRQoL impairment was classified as severe if their Dermatology Life Quality Index Scores were ≥ 11. Factors influencing HRQoL impairment were identified using multivariate logistic regression analysis.

Results

Of the 299 respondents, 161 (53.8%) exhibited severe HRQoL impairment. The Dermatology Life Quality Index scores were significantly associated with gender, annual income, neck psoriasis, psoriasis-related resignation from work, and use of oral and herbal medications. The severity of HRQoL impairment in women was twice that observed in men (odds ratio [OR] = 2.00, 95% confidence interval (CI): 1.05–3.80). Patients with psoriasis on the neck exhibited significantly greater HRQoL impairment than those with psoriasis on other areas of their bodies (OR = 2.30, 95% CI: 1.20–4.43). With respect to the socioeconomic status, patients who earned > 40 million KRW (approximately 34,000 USD; high-income group) showed less HRQoL impairment compared with those who had lower incomes (OR = 0.47, 95% CI: 0.28–0.80). Patients with severe HRQoL impairment used oral (OR = 2.04, 95% CI: 1.20–3.44) and herbal (OR = 1.86, 95% CI: 1.04–3.34) medications more often relative to patients with less severe HRQoL impairment.

Conclusions

HRQoL in patients with psoriasis was significantly associated with their demographic and socioeconomic characteristics and employment status. The presence of psoriasis on exposed areas of the body was significantly associated with patients’ HRQoL and employment status. Further research is required to evaluate the impact of psoriasis on patients’ productivity.

Keywords

  • Psoriasis
  • Quality of life
  • Cross-sectional study
  • Dermatology life quality index

Background

Psoriasis is a multisystem inflammatory disease that is underdiagnosed and undertreated despite its prevalence and considerable effect on quality of life (QoL). Beyond skin and joint involvement, psoriasis is also associated with various important medical and psychiatric conditions that require timely therapy to improve long-term outcomes [1]. Psoriasis is one of the most common chronic skin diseases, affecting a large proportion of the population [2]. Korea National Health Insurance data showed that the number of patients with psoriasis in Korea was 168,862 in 2013 and had increased by 1.5% per year for 5 years from 2011 to 2016. Consequently, the economic burden of disease for psoriasis has also increased from 11 million USD to 21 million USD during this period [3]. Despite this increase in the number of patients and burden of disease for psoriasis, the misconception that skin diseases are less serious relative to other illnesses remains.

Skin diseases, including psoriasis, have been shown to exert a significant adverse effect on patients’ health-related quality of life (HRQoL). Psoriasis can influence various aspects of patients’ lives including their careers, incomes, relationships, and physical intimacy [4, 5]. It can increase in severity, and moderate-to-severe psoriasis could compromise patients’ QoL considerably [6].

Psoriasis could lead to different types of stressful experience for patients [7]. Literature reviews have documented various difficulties in coping with the chronic disease, including those concerning treatment management, symptom control, management of assaults on body image and self-esteem, and the potential to lead a normal life [8]. Individuals differ in their adjustment to a chronic illness. Patients with psoriasis report that the condition has various psychosocial consequences, such as social isolation and feelings of anger, depression, shame, and anxiety [9].

Improvement in QoL is an important treatment goal for patients with psoriasis [10]. HRQoL measures are particularly important for dermatological conditions, as although not usually life-threatening, they frequently exert a strong influence on patients’ psychosocial status, social relationships, and everyday activities. The Body Surface Area (BSA) tool is used to measure patients’ health status; however, objective clinical severity is not always linearly associated with patients’ subjective distress, as one might expect [11].

Therefore, this national study aimed to identify the socioeconomic and clinical characteristics affecting HRQoL in patients with psoriasis, using Internet-based questionnaires.

Methods

Study design and setting

We conducted a cross-sectional study between March and June 2015, using data obtained via an Internet-based survey in Korea. Participants’ socioeconomic and clinical characteristics and HRQoL were examined simultaneously using a structured questionnaire.

Study participants and data collection

The participants were recruited via e-mail and invited to participate in the survey in cooperation with the Korea Psoriasis Association, a nationwide patient association with 17,092 members as of 2015. An invitation letter was sent to 1685 members who had registered for the Association at least once in the past three years as a regular member and were aged 19 years or older (at time of registration). Those invited were informed that they could withdraw their consent at any time during the study without incurring any negative consequences and that their data would be excluded from the study. This study included a total of 299 patients (response rate was 17.7%) who (a) were diagnosed with psoriasis at a clinic or a hospital, (b) signed an informed consent form, and (c) answered all questions. The study protocol was reviewed and approved by the Institutional Review Board at Chung-Ang University (IRB Number: 1041078–201,501-HRSB-007-01).

Measurement

The independent variables included demographic, socioeconomic, and clinical characteristics. Demographic and socioeconomic characteristics included gender, age, marital status, educational level, employment status, annual income, occupation, difficulty securing employment because of psoriasis, and psoriasis-related resignation from work.

Clinical characteristics were examined in terms of duration, severity, affected area of the body, and treatment. Psoriasis severity was assessed according to the BSA affected by psoriasis, using the question “How many times the size of your palm is the entire area in which you have psoriasis?” This measurement was based on the assumption that one’s own palm area represents 1% of one’s BSA [12]. Those with affected BSAs of 10% or larger, 5% to 9%, and 5% or less were classified as patients with severe, moderate, and mild psoriasis, respectively [12, 13].

The Dermatology Life Quality Index (DLQI) was used to evaluate patients’ psoriasis-related HRQoL impairment. The DLQI is a dermatology-specific QoL measuring instrument consisting of 10 questions asking patients to indicate how their skin disease has affected their HRQoL during the preceding week. The sum of the item scores provides a total score between 0 (no impact on HRQoL) and 30 (maximum impact on HRQoL) [1416]. Scores of 11 or higher indicate severe HRQoL impairment. This survey employed a Korean version of DLQI which was validated by the Korean research team and added as a reference to the study [17].

Statistical analysis

Participants’ characteristics are presented as frequencies and proportions for categorical variables and means and standard deviations for continuous variables. Differences were evaluated using chi-squared tests and t tests, as appropriate.

Patients’ DLQI scores were classified into the following five groups: Group 1: participants who reported no effects (scores 0–1), Group 2: participants who reported mild effects (scores 2–5), Group 3: participants who reported moderate effects (scores 6–10), Group 4: participants who reported severe effects (score 11–20), and Group 5: participants who reported very severe effects (scores 21–30), and frequencies and proportions were calculated for each group [18].

Analyses of variance or t tests were performed to compare mean DLQI scores, and a chi-squared test was performed to assess the association of demographic, socioeconomic, and clinical factors with HRQoL in patients with scores of 11 or higher. Factors influencing impairment were identified using multivariate logistic regression analysis with backward elimination of factors with clinical/socioeconomic significance that included gender, age group (< 40 years, ≥40 years), psoriasis severity (BSA < 10%, BSA ≥ 10%), annual income (< 48,000 USD, ≥ 48,000 USD), resignation from work because of psoriasis, psoriasis on the neck, use of oral medication for psoriasis, and use of herbal medication for psoriasis.

Results

Among 1685 patients invited via e-mail, 299 patients voluntarily participated in this survey (response rate, 17.7%). Table 1 shows participants’ characteristics according to gender. Of the 299 participants, 224 (74.9%) were men, who were more likely to be older, married, in full-time employment, and earning higher incomes, relative to women. In addition, women tended to be more likely to have psoriasis on the neck and less likely to receive topical treatment relative to men.
Table 1

Characteristics of study participants with psoriasis by gender

Variables

Total (n = 299)

Male (n = 224)

Female (n = 75)

 

N

(%)

N

(%)

N

(%)

P-value

Gender

 Male

224

(74.9)

     

 Female

75

(25.1)

     

Age (years)

 Mean, SD

43.8

±9.9

45.3

±9.7

39.2

±9.4

< 0.001

 20–39

95

(31.8)

57

(25.4)

38

(50.7)

< 0.001

 40–59

181

(60.5)

146

(65.2)

35

(46.7)

 

 60–79

23

(7.7)

21

(9.4)

2

(2.7)

 

Marital status

 Single

75

(25.1)

48

(21.4)

27

(36.0)

0.038

 Married

196

(65.6)

155

(69.2)

41

(54.7)

 

 Divorced/widowed

26

(8.7)

21

(9.4)

7

(9.3)

 

Education level

  ≤ High school

65

(21.7)

43

(19.2)

22

(29.3)

0.143

 College

183

(61.2)

145

(64.7)

40

(53.3)

 

 Graduate school

49

(16.4)

36

(16.1)

13

(17.3)

 

Employment status

 Full-time

213

(71.2)

171

(76.3)

42

(56.0)

0.003

 Part-time

27

(9.0)

18

(8.0)

9

(12.0)

 

 Unemployed/student/housewife

59

(19.7)

35

(15.6)

24

(32.0)

 

Annual income (USD)

  < 24,000

33

(11.0)

20

(8.9)

13

(17.3)

0.003

 24,000-47,999

99

(33.1)

71

(31.7)

34

(45.3)

 

 48,000-71,999

92

(30.8)

72

(32.1)

20

(26.7)

 

  ≥ 72,000

69

(23.1)

61

(27.2)

8

(10.7)

 

Duration of psoriasis (years)

 Mean, SD

21.3

±10

21.6

±9.7

20.5

±10.8

0.426

 1–9

33

(11.0)

21

(9.4)

12

(16.0)

0.429

 10–19

113

(37.8)

88

(39.3)

25

(33.3)

 

 20–29

89

(29.8)

67

(29.9)

22

(29.3)

 

  ≥ 30

64

(21.4)

48

(21.4)

16

(21.3)

 

Severity of psoriasis (BSA)

 Mild (< 5%)

146

(48.8)

106

(47.3)

40

(53.3)

0.665

 Moderate (5–9%)

65

(21.7)

50

(22.3)

15

(20.0)

 

 Severe (≥10%)

88

(29.4)

68

(30.4)

20

(26.7)

 

Site of psoriasis

 Head

233

(77.9)

179

(79.9)

54

(72.0)

0.153

 Face

141

(47.2)

107

(47.8)

34

(45.3)

0.715

 Neck

82

(27.4)

51

(22.8)

31

(41.3)

0.002

 Shoulder

115

(38.5)

89

(39.7)

26

(34.7)

0.435

 Chest/abdomen

191

(63.9)

141

(62.9)

50

(66.7)

0.562

 Back/buttocks

232

(77.6)

174

(77.7)

58

(77.3)

0.951

 Arm

229

(76.6)

169

(75.4)

60

(80.0)

0.420

 Hand

141

(47.2)

111

(49.6)

30

(40.0)

0.151

 Leg

263

(88.0)

201

(89.7)

62

(82.7)

0.104

 Foot

128

(42.8)

95

(42.4)

33

(44.0)

0.810

Treatment for psoriasis

 Topical treatment

246

(82.3)

190

(84.8)

56

(74.7)

0.046

 Prescribed oral medication

135

(45.2)

97

(43.3)

38

(50.7)

0.267

 Herbal medication

88

(29.4)

62

(27.7)

26

(34.7)

0.250

 Phototherapy

142

(47.5)

110

(49.1)

32

(42.7)

0.334

 Injections except biologics

45

(15.1)

31

(13.8)

14

(18.7)

0.312

 Biological therapy

28

(9.4)

22

(9.8)

6

(8.0)

0.639

BSA body surface area

Participants’ mean DLQI score was 12.4 (SD = 7.6), and 53.8% (n = 161) exhibited severe HRQoL impairment (DLQI scores ≥11). Specifically, the proportions of participants in Groups 1 2, 3, 4, and 5 were 4.0%, 16.7%, 25.4%, 37.1%, and 16.7%, respectively (Fig. 1).
Fig. 1
Fig. 1

Distribution of Dermatology Life Quality Index (DLQI) score (%)

Table 2 shows the participants’ DLQI scores according to their demographic and socioeconomic characteristics. The factors associated with high DLQI scores included female gender and age younger than 40 years, divorce or widowhood, education to high school level or lower, part-time or temporary employment or unemployment, and low income. In addition, DLQI scores were highest in patients who reported that they always or often experienced difficulty securing employment and resigned from work because of psoriasis.
Table 2

DLQI Scores according to demographic and socioeconomic factors in patients with psoriasis

Variables

No. of patients

DLQI Scores

p-value

DLQI ≤10

DLQI ≥11

p-value

Mean ± SD

N

(%)

N

(%)

Total participants

299

12.4 ± 7.6

 

138

(46.2)

161

(53.8)

 

Gender

 Male

224

11.6 ± 7.5

0.003

117

(52.2)

107

(47.8)

< 0.001

 Female

75

14.7 ± 7.7

 

21

(28.0)

54

(72.0)

 

Age (years)

 20–39

95

13.9 ± 8.2

0.038

38

(40.0)

57

(60.0)

0.258

 40–59

181

11.9 ± 7.2

 

87

(48.1)

94

(51.9)

 

 60–79

23

10.3 ± 7.5

 

13

(56.5)

10

(43.5)

 

Marital status

 Single

75

14.7 ± 8.3

< 0.001

29

(38.7)

46

(61.3)

0.009

 Married

196

11.0 ± 6.9

 

102

(52.0)

94

(48.0)

 

 Divorced/widowed

28

15.9 ± 8.0

 

7

(25.0)

21

(75.0)

 

Education level

  ≤ High school

65

14.8 ± 7.4

0.010

21

(32.3)

44

(67.7)

0.029

 College

183

11.5 ± 7.4

 

95

(51.9)

90

(49.2)

 

 Graduate school

49

12.6 ± 8.0

 

22

(44.9)

27

(55.1)

 

Employment status

 Full-time

213

11.4 ± 7.2

0.002

106

(49.8)

107

(50.2)

0.127

 Part-time

27

15.8 ± 8.2

 

9

(33.3)

18

(66.7)

 

 Unemployed/student/housewife

59

14.3 ± 8.1

 

23

(39.0)

36

(61.0)

 

Type of employment

 Employer or self-employed

59

11.2 ± 6.8

< 0.001

31

(52.5)

28

(47.5)

0.098

 Regular job

159

11.4 ± 7.2

 

78

(49.1)

81

(50.9)

 

 Temporary job

17

18.2 ± 8.8

 

4

(23.5)

13

(76.5)

 

 Unemployed

64

14.5 ± 8.0

 

25

(39.1)

39

(60.9)

 

Annual income (USD)

  < 24,000

33

18.3 ± 8.3

< 0.001

7

(21.2)

26

(78.8)

< 0.001

 24,000-47,999

105

13.9 ± 7.2

 

38

(36.2)

67

(63.8)

 

 48,000-71,999

92

10.7 ± 7.3

 

49

(53.3)

43

(46.7)

 

  ≥ 72,000

69

9.5 ± 6.2

 

44

(63.8)

25

(36.2)

 

Experience of difficulty in finding jobs due to psoriasis

 Always/often

87

17.9 ± 7.3

< 0.001

15

(17.2)

72

(82.8)

< 0.001

 Somewhat/sometimes/never

212

10.1 ± 6.5

 

123

(58.0)

89

(42.0)

 

Experience of quitting jobs due to psoriasis

 Yes

92

15.9 ± 8.0

< 0.001

23

(25.0)

69

(75.0)

< 0.001

 No/Inapplicable

207

10.8 ± 6.9

 

115

(55.6)

92

(44.4)

 

DLQI Dermatology life quality index

Patients with severe psoriasis (BSA ≥ 10%) exhibited high DLQI scores (15.0 ± 8.0), indicating severe HRQoL impairment (Table 3). Further, DLQI scores in patients with psoriasis on the face, neck, shoulder, or foot were significantly higher relative to those observed in patients with psoriasis on other areas of the body (p < .001). Patients who used oral or herbal medication exhibited greater HRQoL impairment relative to those who did not use these medications (p < .05).
Table 3

DLQI Scores by clinical factors in patients with psoriasis

Variables

No. of patients

DLQI Scores

p-value

DLQI ≤10

DLQI ≥11

p-value

Mean ± SD

N

(%)

N

(%)

Total participants

299

12.4 ± 7.6

 

138

(46.2)

161

(53.8)

 

Duration of psoriasis (years)

 1–9

33

14.8 ± 8.3

0.201

14

(42.4)

19

(57.6)

0.661

 10–19

113

12.6 ± 7.8

 

50

(44.2)

63

(55.8)

 

 20–29

89

11.5 ± 7.6

 

46

(51.7)

43

(48.3)

 

  ≥ 30

64

12.0 ± 6.9

 

28

(43.8)

36

(56.3)

 

Severity of psoriasis (BSA)

 Mild (< 5%)

146

10.5 ± 6.9

< 0.001

80

(54.8)

66

(45.2)

0.005

 Moderate (5–9%)

65

13.0 ± 7.6

 

29

(44.6)

36

(55.4)

 

 Severe (≥10%)

88

15.0 ± 8.0

 

29

(33.0)

59

(67.0)

 

Site of psoriasis

 Head

233

13.0 ± 7.8

0.010

101

(43.3)

132

(56.7)

0.067

 Face

141

14.4 ± 8.2

< 0.001

54

(38.3)

87

(61.7)

0.010

 Neck

82

16.0 ± 7.5

< 0.001

21

(25.6)

61

(74.4)

< 0.001

 Shoulder

115

15.2 ± 7.8

< 0.001

41

(35.7)

74

(64.3)

0.004

 Chest/abdomen

191

13.5 ± 7.6

0.001

74

(38.7)

117

(61.3)

0.001

 Back/buttocks

232

13.5 ± 7.7

< 0.001

93

(40.1)

139

(59.9)

< 0.001

 Arm

229

13.2 ± 7.8

0.001

97

(42.4)

132

(57.6)

0.017

 Hand

141

14.2 ± 7.7

< 0.001

51

(36.2)

90

(63.8)

0.001

 Leg

263

12.4 ± 7.7

0.916

120

(45.6)

143

(54.4)

0.622

 Foot

128

14.7 ± 7.6

< 0.001

43

(33.6)

85

(66.4)

< 0.001

Treatment for psoriasis

 Topical treatment

246

12.8 ± 7.6

0.048

107

(43.5)

139

(56.5)

0.047

 Prescribed oral medication

135

14.8 ± 7.9

< 0.001

44

(32.6)

91

(67.4)

< 0.001

 Herbal medication

88

14.2 ± 7.8

0.009

30

(34.1)

58

(65.9)

0.007

 Phototherapy

142

13.8 ± 8.1

0.002

57

(40.1)

85

(59.9)

0.047

 Injections except biologics

45

15.1 ± 8.6

0.011

16

(35.6)

29

(64.4)

0.122

 Biological therapy

28

11.8 ± 8.9

0.636

14

(50.0)

14

(50.0)

0.668

DLQI Dermatology life quality index; BSA: body surface area

The proportion of HRQoL impairment level observed in women was twice that observed in men (odds ratio [OR] = 2.00, 95% confidence interval [CI]: 1.05–3.80). Patients with psoriasis on the neck exhibited significantly greater HRQoL impairment relative to those with psoriasis in other areas of the body (OR = 2.30, 95% CI: 1.20–4.43). Regarding socioeconomic status, patients who earned 40 million KRW (approximately 48,000 USD) or more showed lower levels of HRQoL impairment than those who had lower incomes (OR = 0.47, 95% CI: 0.28–0.80). Patients with severe HRQoL impairment used oral (OR = 2.04, 95% CI: 1.20–3.44) or herbal (OR = 1.86, 95% CI: 1.04–3.34) medications more frequently than those with less severe HRQoL impairment (Table 4).
Table 4

Factors influencing HRQoL impairment

Variables

Crude odds ratio (95% CI)

Adjusted odds ratio (95% CI)

Female

2.812

(1.593–4.963)

1.996

(1.048–3.800)

Age of 40 years or older

0.693

(0.423–1.136)

1.311

(0.719–2.389)

BSA ≥ 10%

2.174

(1.292–3.657)

1.383

(0.739–2.589)

Annual income ≥ USD 48,000

0.354

(0.220–0.568)

0.471

(0.276–0.804)

Experience of quitting jobs due to psoriasis

3.750

(2.173–6.472)

2.158

(1.172–3.972)

Psoriasis on neck

3.399

(1.935–5.969)

2.304

(1.199–4.428)

Use of oral drugs for psoriasis

2.777

(1.728–4.464)

2.036

(1.204–3.443)

Use of oriental medicines for psoriasis

2.027

(1.209–3.399)

1.859

(1.035–3.341)

Dermatology life quality index cutoff score for severe quality of life impairment: ≥11, HRQoL health-related quality of life, BSA body surface area, CI confidence interval

Discussion

The results showed that HRQoL in patients with psoriasis was significantly associated with their demographic and socioeconomic characteristics and employment status. In addition, the presence of psoriasis on exposed areas was significantly associated with patients’ HRQoL and employment status. Visibility is associated with self-esteem because appearance plays an important role in social and cultural settings [19]. However, the overall Psoriasis Area Severity Index (PASI) score is weighted only by regional body surface area (BSA), failing to account for a disproportionate burden in more visible/sensitive locations [7, 8]. Given that the burden of psoriasis may be related to disease location and associated with QoL [8], further research examining the impact of psoriasis on patient productivity is required.

Psoriasis has been associated with significant psychological distress, psychiatric morbidity, stigma, and reductions in HRQoL [20]. In addition, the clinical severity of the condition, measured using the PASI, has been associated with patients’ QoL [21]. In the current study, the results showed that women were more likely to feel distressed or embarrassed about psoriasis relative to men. This finding is consistent with those of previous research conducted by Finlay et al., wherein men found it easier to cope with the social effects of psoriasis than women [22, 23]. Furthermore, stress research has provided an additional method for enhancing the understanding of differences between reactions of men and women’s toward psoriasis and indicated that women are more susceptible to stress [24, 25]. Consequently, stress is more likely to exert a stronger impact on the psychological aspects of HRQoL in women than men [26]. Therefore, the findings of this present study are congruent with those of previous studies. Moreover, some previous studies have shown that women were more likely to react to stress and the displayed greater discomfort and stigmatization than men [25, 27]. In addition, gender differences were observed in Short Form-12 mental component summary scores but not in general physical or skin-related HRQoL [25].

With respect to financial status, a meaningful difference in HRQoL was observed between participants with annual incomes greater than 40 million KRW (48,000 USD) and those with annual incomes less than that. The Korean government established a maximum out-of-pocket payment limit to reduce patients’ financial burden resulting from excessive medical expenses. This established limit is designed to cover excesses above the individual limit by income level and is implemented through the National Health Insurance Service. However, under the system, patients with low income cannot take advantage of their insurance benefit because they may have to pay a substantial out-of-pocket medical fee for psoriasis treatment and wait for 20 months for their refund. This may make it difficult to access more expensive and effective treatment options, such as biologics, which can lead to low QoL [18].

Additionally, patients’ job security is dependent on their disease severity, as it reduces their ability to work and may lead to early retirement [28]. In a previous study, patients with moderate-to-severe psoriasis were estimated to experience a significant (15–20%) reduction in their ability to work following diagnosis [29]. In another study, participants’ productivity scores were negatively associated with disease severity, indicating greater impairment in patients with severe psoriasis, as they experienced symptoms of greater intensity and a larger reduction in HRQoL and productivity, relative to those experienced by patients with mild or moderate psoriasis [30]. Therefore, physicians should be mindful of the impact of severe disease on patients’ lives, including employment, and endeavor to address this issue.

In recent literature, attention has been focused on the role of psychological factors in the frequency of recurrence and remission, and treatment dynamics [31] because the skin is important to aesthetics and appearance. It is also an important factor in nonverbal communication and interpersonal relationships, partly because it is involved in emotional expression. Therefore, chronic dermatological conditions exert a significant effect on patients’ psychological health, self-esteem, and body image. Understandably, patients are very anxious about psoriasis on the neck, as it is difficult to conceal from others. Chronic stress and the related loss of positive self-image could also lead to social rejection, which is likely to exacerbate psoriatic symptoms [32]. Consequently, stress could be considered a prognostic factor for psychosocial dysfunction in patients with psoriasis. Moreover, reduction of emotional well-being in proportion to the severity of skin changes could lead to reductions in subjective QoL and psychological functioning.

With respect to treatment, topical therapy, such as steroid cream or lotion, is frequently used to treat mild or moderate psoriasis. In addition, anthralin, tar, vitamin D derivatives (i.e., calcipotriol), and vitamin A (i.e., tazarotene) are popular oral medications, and systemic treatment for severe psoriasis includes methotrexate and cyclosporine as standard medication options in Korea. However, systemic treatments are likely to include side effects, such as clinically significant liver enzyme abnormalities, which could influence patients’ QoL.

Psoriasis patients often enquire about the use of numerous herbal and oriental medicines; therefore, dermatologists should keep abreast of contemporary evidence regarding these agents. However, health professionals are cautious in their use of herbal medications, particularly those for psoriasis, because of availability and quality issues identified via research [33].

This research was conducted with a limited number of patients who were registered in a patient group. In addition, the participants completed the questionnaires online; consequently, the study was restricted to patients who were available and able to use the Internet and a computer, which could have led to response bias and limited the generalizability of the findings to other patient groups. Furthermore, according to a previous study, in South Korea as of 2015, the male-to-female ratio of patients with psoriasis was 1.3:1, and the percentage of elderly patients over 60 years old with psoriasis was 25% [34]. Compared with the entire psoriasis population, the present study included fewer women (25.1%) with a lower QoL, and the results may be underestimated. On the other hand, there is a possibility that the results are overestimated because of the inclusion of fewer elderly people (7.7%) with a higher QoL. In terms of research design, these findings could not explain the robust causal inference because this study was performed using a cross-sectional design and may only able to provide snapshots of psoriasis patients’ current situations. In addition, further research is required to examine the impact of psoriasis on patient productivity.

Conclusion

Treatment goals and success should be based on patients’ QoL in the provision of patient-centered care. However, treatment outcomes can be measured easily using objective criteria such as the Patient Benefit Index global score and the PASI. Therefore, patients’ demographic and socioeconomic characteristics and employment status may be ignored, despite being significantly associated with psoriasis patients’ HRQoL. Patients’ employment status and the presence of psoriasis in exposed areas could be significantly associated with their QoL and satisfaction with treatment. Through this research, it was shown that HRQoL of psoriasis patients was a major factor in managing the disease. Therefore, when physicians and patients set treatment goals together, key factors affecting QoL should be considered.

Notes

Abbreviations

BSA: 

Body surface area

DLQI: 

Dermatology Life Quality Index

HRQoL: 

Health-related quality of life

PASI: 

Psoriasis Area Severity Index

QoL: 

Quality of life

Declarations

Acknowledgements

The authors would like to thank all the participants and the Korea Psoriasis Association for their assistance in the data collection.

Availability of data and materials

Data are available from the authors upon reasonable request.

Authors’ contributions

SJ and SML designed the study, performed the statistical analyses, and drafted and critically revised the manuscript. DS and HTS critically revised the manuscript. DCS contributed to the research question, study design, funding acquisition, and the drafting and final approval of the manuscript. DCS is the guarantor of this work, and as such, had full access to all the data in the study and accepts responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This research was approved by the Institutional Review Board of Chung-Ang University, and all participants provided written informed consent for the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
College of Pharmacy, Sookmyung Women’s University, Seoul, South Korea
(2)
College of Pharmacy, Chung-Ang University, Seoul, South Korea
(3)
Mailman School of Public Health, Columbia University, New York, NY, USA

References

  1. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–85.PubMedPubMed CentralGoogle Scholar
  2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–96.View ArticlePubMedGoogle Scholar
  3. Health Insurance Review & Assessment Service. Healthcare Bigdata Hub. http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do. Accessed 16 Nov 2017.
  4. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49:S57–61.View ArticlePubMedGoogle Scholar
  5. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.View ArticlePubMedGoogle Scholar
  6. Pathirana D, Nast A, Ormerod AD, Reytan N, Saiag P, Smith CH, Spuls P, Rzany B. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol. 2010;24:1458–67.View ArticlePubMedGoogle Scholar
  7. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997;137:755–60.View ArticlePubMedGoogle Scholar
  8. Moos RH. Coping with physical illness II: new perspectives. New York: Plenum Medical Book Co; 1989.Google Scholar
  9. Gupta MA, Gupta AK, Haberman HF. Psoriasis and psychiatry: an update. Gen Hosp Psychiatry. 1987;9:157–66.View ArticlePubMedGoogle Scholar
  10. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5:566–74.View ArticlePubMedGoogle Scholar
  11. Fortune DG, Richards HL, Main CJ, Griffiths CEM. What patients with psoriasis believe about their condition. J Am Acad Dermatol. 1998;39:196–201.View ArticlePubMedGoogle Scholar
  12. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281–5.View ArticlePubMedGoogle Scholar
  13. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53:101–7.View ArticlePubMedGoogle Scholar
  14. Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.View ArticlePubMedGoogle Scholar
  15. Loo WJ, Diba V, Chawla M, Finlay AY. Dermatology life quality index: influence of an illustrated version. Br J Dermatol. 2003;148:279–84.View ArticlePubMedGoogle Scholar
  16. Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169–80.View ArticlePubMedGoogle Scholar
  17. Department of Dermatology. DLQI Different Language Versions. Cardiff University. http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-different-language-versions. Accessed 10 Oct 2017.
  18. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659–64.View ArticlePubMedGoogle Scholar
  19. Fox FE, Rumsey N, Morris M. “Ur skin is the thing that everyone sees and you cant change it!”: exploring the appearance-related concerns of young people with psoriasis. Dev Neurorehabil. 2007;10:133–41.View ArticlePubMedGoogle Scholar
  20. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20:53–63.View ArticlePubMedGoogle Scholar
  21. Geale K, Henriksson M, Schmitt-Egenolf M. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. Health Qual Life Outcomes. 2017;15:151.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol. 1990;123:751–6.View ArticlePubMedGoogle Scholar
  23. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000;70:567–71.View ArticlePubMedGoogle Scholar
  24. Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Italian multipurpose psoriasis research on vital experiences study G: age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154:325–31.View ArticlePubMedGoogle Scholar
  25. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B. Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol. 2004;18:27–36.View ArticlePubMedGoogle Scholar
  26. Bougueon K, Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135(4):S254–8.View ArticlePubMedGoogle Scholar
  27. Matud MP. Gender differences in stress and coping styles. Personal Individ Differ. 2004;37:1401–15.View ArticleGoogle Scholar
  28. Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23:208–11.PubMedGoogle Scholar
  29. Chan B, Hales B, Shear N, Ho V, Lynde C, Poulin Y, Mittmann N. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13:192–7.View ArticlePubMedGoogle Scholar
  30. Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41:514–21.View ArticlePubMedGoogle Scholar
  31. Basinska MA, Drozdowska M. Emotional intelligence as an indicator of satisfaction with life of patients with psoriasis. Postepy Dermatol Alergol. 2013;30:365–72.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Gupta MA, Gupta AK. Quality of life of psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14:241–2.View ArticlePubMedGoogle Scholar
  33. Farahnik B, Sharma D, Alban J, Sivamani RK. Topical botanical agents for the treatment of psoriasis: a systematic review. Am J Clin Dermatol. 2017;18:451–68.View ArticlePubMedGoogle Scholar
  34. Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance Database. Ann Dermatol. 2017;29:761–7.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement